64/100B39.440
USD
-0.54
(-1.35%)
Market Closed
Last updated: · Delayed 15 min
Medline stock forecast 2025–2027What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Medline is 44.20, 12.1% above the current price of 39.44. Their targets range from 37.00 to 55.00.
Of the 19 firms that rated Medline in the past 12 months, 17 rate it buy or strong buy, 2 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
12-month price target
44.20 USD
+12.07%
Analysts' 1-year price targets range from 37.00 to 55.00, with an average of 44.20.
Past year
1-year forecast
Strong sellStrong buy
Strong buy
19 ratings
| Buy | 17 | |
| Hold | 2 | |
| Sell | 0 |
12-month price target
| Highest target | 55.00 |
| Average target | 44.20 |
| Lowest target | 37.00 |
| Current price | 39.44 |
Medline price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
See how analysts moved their price target
How analysts rate Medline, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
17 of 19 firms rate it buy now, against 5 of 6 in February 2026.
Buy Hold Sell
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Medline analyst upgrades, downgrades and price targets
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 22 Oct 2026 | Mizuho Securities Steven Valiquette | Reiterated · Outperform | 48.00 → 45.00 | -6.3% | 35.31 |
| 9 Oct 2026 | Barclays | Reiterated · Overweight | 45.00 → 43.00 | -4.4% | 35.74 |
| 25 Sept 2026 | UBS Kevin Caliendo | Reiterated · Buy | 48.00 → 43.00 | -10.4% | 34.81 |
| 27 Aug 2026 | BTIG David Larsen | Reiterated · Buy | 50.00 → 55.00 | +10.0% | 34.58 |
| 6 Aug 2026 | Robert W. Baird Eric Coldwell | — | 45.00 → 42.00 | -6.7% | 35.30 |
| 6 Aug 2026 | Evercore ISI | Reiterated · Outperform | 55.00 → 39.00 | -29.1% | 35.71 |
| 6 Aug 2026 | Stifel Nicolaus | Reiterated · Buy | 55.00 → 45.00 | -18.2% | 35.54 |
| 6 Aug 2026 | BMO Capital Sean Dodge | — | 45.00 → 47.00 | +4.4% | 36.67 |
| 6 Aug 2026 | RBC Capital | Reiterated · Outperform | 47.00 → 46.00 | -2.1% | 36.67 |
| 6 Aug 2026 | Deutsche Bank | — | 42.00 → 37.00 | -11.9% | 36.67 |
| 3 Jun 2026 | Robert W. Baird Eric Coldwell | — | 48.00 → 45.00 | -6.3% | 33.19 |
| 1 Jun 2026 | Barclays Glen Santangelo | Reiterated · Overweight | 50.00 → 45.00 | -10.0% | 36.56 |
| 7 May 2026 | Deutsche Bank | — | 40.00 → 42.00 | +5.0% | 41.95 |
| 9 Mar 2026 | Tigress Financial Ivan Feinseth | Reiterated · Buy | 55.00 → 60.00 | +9.1% | 43.41 |
| 25 Feb 2026 | Leerink Partners Michael Cherny | — | 48.00 → 56.00 | +16.7% | 48.18 |
| 25 Feb 2026 | Stifel Nicolaus | — | 46.00 → 55.00 | +19.6% | 48.18 |
| 25 Feb 2026 | Evercore ISI | — | 50.00 → 55.00 | +10.0% | 49.38 |
| 5 Feb 2026 | Tigress Financial | — | 55.00 | — | 45.01 |
| 21 Jan 2026 | J.P. Morgan David Larsen | — | 55.00 | — | 43.17 |
| 12 Jan 2026 | Barclays | — | 50.00 | — | 41.65 |
| 12 Jan 2026 | BNP Paribas | — | 38.00 | — | 42.19 |
| 12 Jan 2026 | Wolfe Research | — | 47.00 | — | 41.88 |
| 12 Jan 2026 | Deutsche Bank | — | 40.00 | — | 40.52 |
| 12 Jan 2026 | Wells Fargo | — | 42.00 | — | 40.52 |
| 12 Jan 2026 | BTIG | — | 50.00 | — | 40.52 |
| 12 Jan 2026 | Mizuho Securities | — | 48.00 | — | 40.52 |
| 12 Jan 2026 | UBS | — | 48.00 | — | 40.52 |
| 12 Jan 2026 | Stifel Nicolaus | — | 46.00 | — | 40.52 |
| 12 Jan 2026 | Redburn Partners Ed Ridley-Day | — | 42.00 | — | 40.52 |
| 12 Jan 2026 | Leerink Partners | — | 48.00 | — | 40.52 |
| 12 Jan 2026 | Evercore ISI Elizabeth Anderson | — | 50.00 | — | 40.52 |
| 12 Jan 2026 | Bernstein | — | 49.00 | — | 40.52 |
| 12 Jan 2026 | Truist Financial | — | 52.00 | — | 40.52 |
| 12 Jan 2026 | Piper Sandler Jason Bednar | — | 50.00 | — | 40.52 |
| 12 Jan 2026 | Robert W. Baird Eric Coldwell | — | 48.00 | — | 40.52 |
| 12 Jan 2026 | BMO Capital Sean Dodge | — | 45.00 | — | 40.52 |
| 12 Jan 2026 | Goldman Sachs David Roman | — | 49.00 | — | 40.52 |
| 12 Jan 2026 | RBC Capital | — | 47.00 | — | 40.52 |
| 11 Jan 2026 | Morgan Stanley Patrick Wood | — | 48.00 | — | 40.52 |
Medline EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Revenue
ReportedEstimate
EPS
ReportedEstimate
Does Medline beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 21.9% off the result, either way, and their revenue estimate 2.6%, over the last 4 quarters.
- EPS beats
- 3 / 4
- Revenue beats
- 4 / 4
- Average EPS surprise, last 4What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +19.1%
- Since
- February 2026
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 4 Nov 2026 | 0.34 | 0.44 | +28.2% | 7.72B | 7.86B | +1.7% |
| Q2 FY2026 | 5 Aug 2026 | 0.35 | 0.50 | +41.9% | 7.52B | 7.69B | +2.2% |
| Q1 FY2026 | 6 May 2026 | 0.30 | 0.33 | +11.8% | 7.16B | 7.35B | +2.6% |
| Q4 FY2025 | 25 Feb 2026 | 0.24 | 0.22 | -5.6% | 7.51B | 7.79B | +3.7% |
Medline stock price 2025–2027: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
Bull Base Bear
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2025 | 1.20 | 32.45 | 46.20 | 70.81 |
| FY2026 | 1.54 | 41.60 | 59.22 | 90.78 |
| FY2027 | 1.55 | 41.85 | 59.58 | 91.33 |
Each year's EPS is the analysts' consensus to FY2027; the years after grow 0.0% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (27.0, 38.4, 58.9).
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.760 | 71.4258Price 35.76193 | +99.7% | |
| 29.080 | 56.2434Price 29.0896 | +93.4% | |
| 240.360 | 464.26205Price 240.36627 | +93.2% | |
| 202.040 | 384.58163Price 202.042,644 | +90.3% | |
| 161.340 | 305.52160Price 161.34396 | +89.4% | |
| 125.395 | 237.44178Price 125.40297 | +89.4% | |
| 159.580 | 300.48225Price 159.58376 | +88.3% |
Furthest below the fair value on each stock's page, updated every day.